Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.

Israeli Ministry Of Health Approves National Coverage For CytoSorb

PRINCETON, N.J., Aug. 17, 2022 /PRNewswire/ — CytoSorbents Corporation (NASDAQ:CTSO), a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery using blood purification via
byBill Haddad
August 17, 2022
1 minute read
Total
0
Shares
0
0
0
0
0
0

PRINCETON, N.J., Aug. 17, 2022 /PRNewswire/ — CytoSorbents Corporation (NASDAQ:CTSO), a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery using blood purification via its proprietary polymer adsorption technology, announced that the Israeli Ministry of Health (MoH) has approved national reimbursement for CytoSorb® in certain cardiac surgery indications that is expected to take effect in 2023.

 
Total
0
Shares
Share 0
Tweet 0
Share 0
Share 0
Share 0
Share 0
Related Posts
Read More

Nurix Announces Initial NX-1607 Phase 1 Data Presented At The 37th Annual Meeting Of The Society For Immunotherapy Of Cancer Demonstrating Targeted CBL-B Inhibition In Patients With Advanced Malignancies

By Benzinga Newsdesk
November 10, 10:20 AM
Biomarker results are a positive demonstration of target engagement for this first-in-class CBL-B inhibitor Biomarker levels achieved with NX-1607 treatment correspond to levels associated with potent anti-tumor

NRIX

Read More

Independent Data Monitoring Committee Completed Its Prespecified Review Of Interim Safety Data In Phio Pharmaceuticals’s Phase 1B Trial Of Ph-762 For Advanced Melanoma, Recommending The Study To Continue Without Modification.

By Benzinga Newsdesk
February 10, 8:33 AM
PH-762 is an INTASYL compound that reduces the expression of cell death Protein 1 (PD-1), a protein that inhibits T cells' ability to kill cancer cells. Decreasing the expression of PD-1 increases the capacity of T

PHIO